Abstract
Objective To understand the screening and treatment of rifampicin-resistant pulmonary tuberculosis (TB) patients in Inner Mongolia autonomous region from 2015 to 2020 and provide evidence for the development of local drug-resistant TB prevention and treatment strategies. Methods The medical records of TB patients and the data of rifampicin resistant pulmonary TB patient screening and treatment in Inner Mongolia from 2015 to 2020 were collected from “Tuberculosis Information Management System”, the rate and composition ratio were used for descriptive statistical analysis. Results The screening rate of rifampicin resistance was 60.7% in new pathogenic positive pulmonary TB patients and 72.2% in high-risk group in Inner Mongolia during 2015–2020, and the rifampicin resistance screening rates increased year by year (trend χ2=36625, P Conclusion The rate of rifampicin resistance screening and the rate of treatment in pathogenic positive pulmonary TB patients in Inner Mongolia increased year by year.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call